Acura Pharmaceuticals Inc.

05/07/2026 | Press release | Distributed by Public on 05/07/2026 06:51

Material Agreement, Asset Transaction, Financial Obligation (Form 8-K)

Exhibit 99.1

Amended Loan Schedule to Secured Promissory Note dated November 10, 2022

between Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC

Date Principal Aggregated
Principal
Original Secured Promissory Note 11/10/2022 $ 2,319,279 $ 2,319,279
Additional Loans to be included:
Loans #1 dated 12/22/2022 through Loans #50 dated 12/31/2025 $ 7,075,000 $ 9,394,279
Loan #51 1/02/2026 $ 100,000 $ 9,494,279
Loan #52 1/16/2026 $ 100,000 $ 9,594,279
Loan #53 2/06/2026 $ 100,000 $ 9,694,279
Loan #54 2/13/2026 $ 100,000 $ 9,794,279
Loan #55 3/09/2026 $ 100,000 $ 9,894,279
Loan #56 3/30/2026 $ 100,000 $ 9,994,279
Loan #57 4/03/2026 $ 100,000 $ 10,094,279
Loan #58 4/20/2026 $ 100,000 $ 10,194,279
Loan #59 5/05/2026 $ 100,000 $ 10,294,279

ACURA PHARMACEUTICALS, INC.

By: /s/ Robert A. Seiser
Robert A. Seiser
Senior Vice President & CFO
Date: May 5, 2026
Acura Pharmaceuticals Inc. published this content on May 07, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 07, 2026 at 12:51 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]